Summary Cisplatin is one of the most active cytotoxic agents in the treatment of testicular cancer, but its clinical use is associated with side-effects such as ototoxicity, neurotoxicity and nephrotoxicity. Long-term kidney damage from cisplatin particularly affects the proximal tubular apparatus and can be detected by increased urinary excretion of brush-border enzymes, such as L-alanine-aminopeptidase (AAP), and magnesium. In the current study, the flavonoid silibinin was used as a nephroprotectant for cisplatin-induced nephropathy in a rat animal model. Infusion of silibinin before cisplatin results in a significant decrease in glomerular (indicated by creatinine clearance and serum urea level) and tubular kidney toxicity (excretion of brush-border enzymes and magnesium). Silibinin given alone had no effect on renal function. In order to exclude an inhibition of the anti-tumour activity of cisplatin and 4-hydroperoxy-ifosfamide by coadministration of silibinin, in vitro studies were performed in three established human testicular cancer cell lines. Dose-response curves for cisplatin (3-30 000 nmol) combined with non-toxic silibinin doses (7.25 x 10-6 or 7.25 x 10-5 mol 1-1) did not deviate significantly from those of cisplatin alone as measured by relative cell survival during a 5 day assay using the sulphorhodamine-B staining technique. Also silibinin did not influence the cytotoxic activity of 4-hydroperoxy-ifosfamide (30-10 000 nmol) in vitro. In summary, these in vitro data rule out a significant inhibition of the anti-tumour activity of the major nephrotoxic components, cisplatin and 4-hydroperoxy-ifosfamide, by co-administration of silibinin in a human germ cell tumour cell line model. Together with these demonstrated cytoprotection effects in the rat animal model, these data form the basis for a randomised clinical trial of silibinin for the protection of cisplatin-associated nephrotoxicity in patients with testicular cancer.
With the introduction of cisplatin-based combination chemotherapy, testicular cancer has become a highly curable malignancy even in patients with metastatic disease (Williams et al., 1987; Einhorn et al., 1977) . Approximately 75 -80% of all patients can expect to be cured by standard combination chemotherapy, such as PEB (cisplatin, etoposide and bleomycin) or PEI (cisplatin, etoposide and ifosfamide) . Based on the advances achieved by the use of cisplatinbased chemotherapy, interest has now also focused on treatment-related toxicity. Cisplatin (DDP) represents one of the most active cytotoxic agents in the treatment of testicular cancer, but its clinical use is associated with particular side-effects, such as ototoxicity, neurotoxicity and nephrotoxicity (Bitran et al., 1982; Hacke et al., 1983; Werner-Hansen et Schilsky et al., 1982) . The risk of DDP-associated nephrotoxicity has been reduced by the use of hyperhydration and forced diuresis, but persistent kidney damage is still found in some patients (Daugaard et al., 1988a) . The effects of DDP on renal function have been extensively studied in animal models. In a rat model the type of DDP nephrotoxicity seems similar to humans, affecting different segments of the nephron, such as the tubular apparatus and the glomerulus (Jones et al., 1985; Safirstein et al., 1981) . Impaired transport processes occur at the luminal and to a lesser degree at the contra-luminal side of the proximal tubular membrane and morphological examinations have revealed necrotic cells in the proximal tubules (Ammer et al., 1993; Field et al., 1989) . The mechanisms of DDP nephrotoxicity are still not fully understood. However, the generation of free oxygen radicals in tubular cells has been proposed as an important pathogenic process (Ishikawa et al., 1990; Hannemann et al., 1988) . Further evidence points to the inhibition of protein synthesis in tubular cells by DDP (Tay et al., 1988) .
The management of nephrotoxicity requires either that
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DDP is discontinued or that doses are reduced. However, this may result in inferior anti-tumour activity. Cytoprotective agents have been developed to ameliorate a variety of functional disorders (Munshi et al., 1992; Anderson et al., 1990) . Silibinin ( Figure 1 ) is one of three isomers constituting silymarin, a flavonoid extracted from Sylibum marianum, the milk thistle, that has long been known as a medicinal plant (Wagner et al., 1974; Hahn and Mayer, 1981) . Silibinin has been successfully used as a protective agent in clinical and in experimental work in in vivo and in vitro models of liver toxicity (Valenzuela and Guerra, 1985; . Silibinin possesses membrane-stabilising, anti-inflammatory, antioxidant and RNA and protein synthesis-stimulating properties (Faulstich et al., 1980; Middleton et al., 1992; Sonnenbichler and Zetl, 1987; Mira et al., 1994) . However, before the clinical use of new cytoprotective agents, not only protection from toxicity, but also the absence of an interference of the agent with the anti-tumour activity of the cytotoxic agents used, have to be demonstrated (Bokemeyer et al., 1994) . The first aim of the preclinical study presented here was to evaluate in vivo the protective effects of the flavonoid silibinin on acute DDP nephrotoxicity in an established rat nephrotoxicity model. Serum and urinary parameters specifically detecting glomerular and tubular damage were therefore studied following treatment with DDP and/or silibinin. The second aim was then to evaluate in vitro, in three human non-seminomatous germ cell tumour cell lines, whether silibinin interferes with the cytotoxicity of DDP and also ifosfamide, which in many standard combination chemotherapies is applied together with DDP.
Materials and methods
In vivo studies on a rat model of DDP nephrotoxicity Female Wistar rats with an initial body weight between 170 and 230 g were used. Animals, housed 3-4 per cage under standardised laboratory conditions with controlled light-dark cycle, room temperature (21 C) and moisture, had free access to tap water and pellet diet (Altromin R, Lage, Germany).
Treatment of animals A total of 45 rats were randomised into four groups. One group received cisplatin (DDP) (n = 12), one group silibinin and DDP (n = 11), one group silibinin alone (n = 10) and one group the vehicle isotonic saline (n = 12). The animals only received one injection of the compounds.
DDP (Medac, Hamburg, Germany) dissolved in saline was given at a concentration of 5 mg kg-' body weight (b.w. (Bradford, 1976) . Changes in urinary L-alanine-aminopeptidase (AAP) activity and urinary magnesium were followed and served as parameters of kidney tubular function. L-alanine-aminopeptidase (AAP, EC 3.4.11) was measured by kinetic determination at 250C, pH 7.6, using L-alanine-4-nitro-anilidehydrochloride as a substrate (Mattenheimer et al., 1992 (Table II) . Plasma levels of urea were concomitantly elevated in the group given DDP, but not in the group that was pretreated with silibinin ( Figure 2) . Tubular function was affected by DDP treatment, indicated by a significant increase in the excretion of AAP. This increase was significantly less pronounced in animals pretreated with silibinin ( Figure 3 ). Mean fractional magnesium excretion ranged from 10 -15% of the filtered magnesium load in the animal group studied during the control phase (day -1). Following cisplatin, an approximately 2.5-fold increase in magnesium excretion was seen, resulting in reduced serum magnesium levels at day 7 in animals receiving DDP alone (0.82+0.05 mmol 1`on day -1, 0.62+0.13 mmoll-' on day 7, P<0.01, t-test). No significant alteration of urinary magnesium excretion and of magnesium serum levels were found when DDP was given after pretreatment with silibinin.
In vitro cytotoxic activity assays on germ cell cancer cell lines Silibinin cytotoxicity Figure 4 shows the dose response curves of the cell lines to silibinin alone. The response of The combined dose -response curves to DDP for cell line 1777 NRCL-A in the presence of 1.45 x 10-4 or 7.25 x 10-4 mol 1-' silibinin were also not significantly different from those of DDP alone. However, a slightly antagonistic interaction between DDP and silibinin at higher doses (7.25 x 10-4 mol 1-') was observed. The highest end of the concentration range of cisplatin studied (10 imol), where antagonism appears to be strongest, represents the peak plasma concentration expected following an intravenous dose of DDP of 100 mg m-2. The in vivo relevance of silibinin concentrations of 7.25 x 10-4 mol l-1 is not known and, therefore, the potential clinical implications are difficult to assess. For cell lines 577 LM and H 12.1, no effect of silibinin on DDP cytotoxicity was observed. Evaluation of the effect of 7.25 x 10-4 mol l-1 silibinin on DDP cytotoxicity was not reliable for these two cell lines, since silibinin alone at this concentration gave only 40% relative cell survival.
In vitro cytotoxicity of 4-hydroperoxy-ifosfamide with or without silibinin Data obtained from four independent experiments consistently showed no influence of silibinin on 4-hydroperoxy-ifosfamide cytotoxicity at any concentration studied in the cell lines 1777 NRCL-A and H 12.1. No differences were observed between hypothetically calculated concentrations of silibinin and 4-hydroperoxy-ifosfamide when compared with the achieved dose -response curve for the combination of both agents. Data for H 12.1 are shown in Figure 6 ; data for 1777 NR CL-A are not given separately.
Discussion
The nephrotoxicity of cisplatin (DDP) has already been recognised during early phase I trials and Hayes et al. (1977) were able to demonstrate that the renal toxicity of high-dose bolus cisplatin (> 100 mg m-2) could be ameliorated by forced diuresis and hydration (Higby et al., 1974) . In order to use DDP in germ cell cancer patients in combination chemotherapy regimens without severe nephrotoxicity, the dose of DDP is usually split to 20 mg m-2x 5 days. This schedule has been incorporated into the formerly used regimen of platin, vinblastine and bleomycin (PVB) and into the current standard PEB regimen (Einhorn et al., 1977; Williams et al., 1987) . Since the nephrotoxicity of DDP seems to be related to peak serum-free platinum levels, DDP bolus doses >100 mg m-2 would be predicted to be more toxic than smaller daily doses such as 20 mg m-2 x 5 days (Reece et al., 1987) . On the other hand, reducing DDP to cumulative doses lower than 75 mg m-2 at 3 week intervals results in inferior survival in patients with metastatic germ cell cancer (Samson et al., 1984) . Thus, adequate platinum dosing appears to be relevant for maintaining cure rates but may also be associated with a higher incidence of acute and late nephrotoxicity (Osanto et al., 1992) . Vigorous hydration using at least 3 1 of normal saline per 24 h before and during cisplatin application, in combination with forced diureses by mannitol or furoseamide are standard precautions taken to prevent DDP nephrotoxicity. Cytoprotective agents, particularly sulphydryl-containing drugs, have been investigated as cytoprotectants against nephrotoxicity (Anderson et al., 1990 ). The current study shows that the flavonoid agent silibinin has a protective effect on renal function. Creatinine clearance and plasma levels of urea were taken as indicators of glomerular function and excretion of a brush-border enzyme and magnesium as indicators of tubular damage.
The changes in renal function observed in the rat model as described above correlate well with the nephrotoxic effects of DDP observed in man (Daugaard et al., 1988b) . Alterations in creatinine clearance and urea serum levels observed following treatment with DDP, but not following treatment with silibinin and DDP (Table II, Figure 1 ), are taken as indications of an altered glomerular function. Creatinine is filtered in the glomerulus, but tubular backleak of creatinine, following, for example, tubular obstruction, can also occur. However, backleak does not play a role in this early stage of nephropathy in the animal model studied (Jones et al., 1985) . Excretion of the tubular enzyme alanine-aminopeptidase (AAP) served as an indicator of proximal tubular function (Pfleiderer et al., 1980; Fels et al., 1994) . Urinary activity of this brush-border enzyme was significantly elevated following treatment of Wistar rats with DDP. This increase was significantly less pronounced in animals that had received silibinin before DDP (Figure 2) . (Valenzuela and Guerra, 1985; Soose, 1994) . Another mechanism of renal toxicity of DDP may be the depression of DNA, RNA and protein synthesis as demonstrated in studies, in vitro (Tay et al., 1988) . Silibinin is known to up-regulate the function of a DNAdependent RNA polymerase I in liver cells (Sonnenbichler et al., 1976; Sonnenbichler and Zetl, 1987) and may thereby counteract the decrease in synthetic activity of the kidney. Thus, the therapeutic activities of silibinin are based on a variety of potentially protective effects. The phenolic structure, for example, makes silibinin a radical scavenger, although it also has membrane-stabilising and regenerative properties (Faulstich et al., 1980; Ferenci et al., 1989; Sonnenbichler and Zetl, 1986) . It is currently difficult to assess which of the properties of the flavonoid are responsible for the protection observed in this study. However, the number of potential mechanisms of action may make silibinin advantageous compared with intracellular radical scavengers, such as sodium thiosulphate. The in vivo studies showed that silibinin at least partly counteracts the nephrotoxic side-effects of DDP. In in vitro studies on human cancer cell lines, it could then be shown that the application of silibinin does not decrease the antitumour activity of either DDP or ifosfamide. Although some cell line-specific differences may exist, the available in vitro data do not indicate a significant interaction of clinically relevant levels of silibinin and the cytotoxic activity of these two major drugs used in testicular cancer. Based on pharmacokinetic studies in patients receiving oral silibinin, the therapeutic plasma levels have reached a maximum of 7.25 x 10' mol I-', a range that has been tested in our experiments (Lorenz et al., 1984) . These levels did not interfere with the anti-tumour activity of cisplatin in vitro. However, adverse pharmacokinetic interactions in vivo had not been addressed in our experiments. Since many attempts to reduce DDP toxicity, e.g. the substitution of DDP by the less nephrotoxic compound carboplatin, have resulted in inferior clinical anti-tumour activity in non-seminomatous germ cell cancer patients, cisplatin still remains the most important drug in the treatment of this disease (Bajorin et al., 1993) . The current data support silibinin as a potentially useful selective cytoprotective agent, which may prevent nephrotoxicity without decreasing cisplatin or ifosfamide anti-tumour activity. Since certain acute renal tubular alterations, such as the elevated excretion of tubular brushborder enzymes, recognised in testicular cancer patients treated with DDP may also be ameliorated by the application of silibinin, it might be speculated that longterm kidney side-effects may also be avoidable. The current data form the basis for a clinical study using cisplatin-based combination chemotherapy including silibinin, in patients with testicular cancer in order to reduce the acute and longterm nephrotoxic potential of cisplatin. A randomised clinical study on kidney function in patients treated for testicular cancer has been initiated.
